Life Science Insights

NIH-funded researchers are brilliant scientists, but most are complete beginners when it comes to reimbursement strategy, design history files, and what the FDA actually cares about. By the time they realize it, they're months from a clinical study with no quality management system and a consultant asking, "Where's your design history file?"In this episode, Andrew J. DiMeo Sr., Ph.D., business advisor for the NIH C3i Program, joins Dan Mazzucco to talk about the commercialization gap in translational research. They discuss the origin of the NIH C3i program and how it evolved from Wallace Coulter Foundation training, the differences among Stanford Biodesign, the Coulter model, and the GAITS framework, why design controls are a framework of relationships rather than a stage-gated process, and why SBIR grants should be thought of as a partnership with taxpayers rather than a funding source.This conversation is for early-stage medtech innovators and academic researchers who suspect the gap between their lab and the market is bigger than they've admitted to themselves.Andrew J. DiMeo Sr., Ph.D., is a biomedical engineer and health innovation leader with over 20 years of experience at the intersection of design, entrepreneurship, and translational research. He is a business advisor for the NIH C3i Program and served as a Team Lead for the NIH RADx Initiative, ITAP, and Blueprint MedTech programs. He co-founded EG-Gilero, a medical device design and manufacturing company, and founded the NC Medical Device Organization, which became an NC Biotech Center of Innovation. For 12 years he was a Professor of the Practice at UNC and NC State, where his students launched multiple startups including 410 Medical, Contour Surgical, and Augment Medical. He is also a contributor to the second edition of the Stanford Biodesign book and the founder of Authbition (authbition.com), a podcast and publication exploring authenticity and ambition.Theme Music: Prelude, by Ben Mazzucco, copyright 2026.

What happens when surgeons casually mention they're not seeing infections at expected rates, and a materials scientist realizes his ceramic spine implants might be doing something no one anticipated?In this episode, SINTX Technologies Chief Technology Officer Ryan Bock joins Dan Mazzucco to talk about the 17-year journey from research scientist to CTO. They discuss the serendipitous discovery of silicon nitride's antibacterial properties, strategic pivoting from hip to spine devices when FDA required expensive trials, navigating workforce reductions with transparency during company restructuring, developing novel silicon nitride/PEEK composites, and the future of additive manufacturing for patient-specific implants.This conversation is for medtech leaders who understand that sometimes the most valuable discoveries come from paying attention to what surgeons notice in the operating room, and who recognize that surviving as a company sometimes means making hard pivots with honesty and empathy.At the time of the interview, Ryan Bock, Ph.D., was the Chief Technology Officer at SINTX Technologies, a publicly traded advanced ceramics company and leading manufacturer of silicon nitride medical devices (he has since moved on). With over 15 patent families to his name and international academic background spanning the US and Japan, Dr. Bock has been with SINTX since 2008. He holds a BS in Materials Science and Engineering from the University of Florida and a PhD from UC Santa Barbara, where he studied under one of the world's foremost experts in silicon nitride. Dr. Bock specializes in surface science and bioceramics, leading development of next-generation medical devices designed to fight infection through advanced silicon nitride technology. He has published extensively on antibacterial properties of silicon nitride and has led SINTX's transition from a spine implant manufacturer to a platform technology company with applications across medical devices, wound care, and filtration.

Most founders think they need money. What they really need is someone who can tell them where their assumptions are wrong before they scale the wrong solution.In this episode, Mohit Prajapati, Chief Innovation Officer at Rift Innovation Studio, joins Dan Mazzucco to discuss the realities of bringing orthopedic and spine technologies from concept to commercialization. They explore stage-fit matching between founders and investors (pre-revenue companies need de-risking capital, not scaling capital), why funding is the least important thing Mohit provided at Penn Medicine's innovation center (knowledge networks and rapid de-risking experiments matter more), the value of pilot launches across university hospitals, community hospitals, and rural trauma centers before scaling, stress-testing assumptions without making it personal (falling in love with the problem rather than the solution), when to show imperfect work versus waiting until it's polished, how universities are building innovation centers to bridge the SBIR funding gap, and why surgeons should stay in the OR while business people run the company (retention through innovation programs beats poaching).This conversation is for medtech founders who understand that the right investor at the wrong stage creates pressure in all the wrong places, and that objective acceptance criteria matter more than whose relationship brought the idea to the table.Mohit Prajapati is med-tech innovator and entrepreneur experienced in working with early-stage startups, large multinational companies, and world-renowned academic centers. He has created new innovation processes and ecosystems to facilitate speed to commercialization for novel solutions that address unmet patient needs. Mohit considers himself fortunate to be working with incredibly talented inventors to create strategic alignment at the intersection of new scientific discovery, product development, care delivery, and business model innovation.

Some people ask AI to write an SOP and are told to eat a few small rocks per day. Spencer Jones uploads 20 documents, writes a 15-minute prompt, and has the model interview him with 40 questions before it generates anything.In this episode, XO Medtech founder Spencer Jones joins Dan Mazzucco to talk about leveraging AI tools for medical device development. They discuss giving AI adequate context (IFUs, BOMs, predicate devices, assembly instructions), why you should treat AI delegation like human delegation, automating meeting transcripts into institutional knowledge, and building agents that turn client calls into airtight proposals. Hear Spencer's hot takes guaranteeing AI security and the future of early-career engineers (spoiler: they won't be replaced but will spend more time on the critical first and last 15% of projects).This conversation is for medtech leaders like Dan who know they need to learn how to use AI tools, but don't know how. Spencer is an RN turned medtech entrepreneur with 12 years of med device leadership. He's a 2x med device CEO (Lapovations, Lineus) with 10+ patents under his belt and has taken devices from idea to FDA clearance and product launch. Spencer has built sales and distribution networks, led product development teams, and raised over $10M in VC/Angel Capital. Spencer founded XO Medtech in 2024 to create a digital medtech ecosystem, to deploy AI native tools for medtech operators (MedtechVendors.com), and to cultivate the next generation of medtech innovators. Track Spencer at www.xomedtech.com, www.medtechvendors.com, or The Medtech Innovation Podcast.

After an injury turned her away from the practice of medicine, Cellia Habita built Europe's largest genetic database for diabetes on her way to two decades of global biotech leadership.In this episode, "the Iron CMO" Cellia Habita joins Dan Mazzucco to talk about transitioning from academic medicine to biotech executive roles. They discuss why fractional CMOs fill a critical gap in early-stage companies, the strategic difference between a CMO and a CRO, how to select clinical trial sites that actually understand your patient population, the realities of working across 25 countries including underserved regions like MENA and Africa, and why eight protocol amendments may mean someone didn't do their homework.This conversation is for biotech leaders who understand that throwing your study to a CRO and expecting magic is not a strategy, and who recognize that the best clinical programs require both strategic medical leadership and tactical execution working hand-in-hand.Cellia Habita, MD, PhD, serves or has served as fractional CMO for multiple biotech companies. She served as CEO of Immodulon Therapeutics and, before that, was CEO of Arianne Corporation, a global clinical research organization providing clinical and regulatory services across 25 countries. Dr. Habita holds an MD from medical training in Paris and a PhD in Genetics from Oxford University and Paris VII, completed during a Wellcome Trust fellowship. She completed a postdoctorate in gene therapy at UC San Diego under Ted Friedman, considered the father of gene therapy in the United States. Dr. Habita has over 20 years of global leadership experience advancing innovative therapies across oncology and rare diseases, guiding programs from pre-IND through pivotal Phase 3 clinical trials and regulatory approval in the US and globally. Her career spans roles at Adventrx Pharmaceuticals (VP and Senior VP of Clinical and Medical Affairs), Immodulon Therapeutics (CEO and CMO), and founding Arianne, which specializes in conducting clinical trials in underrepresented regions including the Middle East, North Africa, and sub-Saharan Africa. She has published research on diabetes genetics, aging, and gene therapy, and has been instrumental in establishing Algeria and other MENA countries as viable centers for clinical research.Known by friends and enemies alike as the Iron CMO, you do not want to be the one telling Cellia that the clinical trial will be delayed a day because the person delivering the Investigator's Brochures was in a car accident and is unable to make it to the investigators' meeting.

Sudden cardiac arrest kills 300,000 Americans each year. The standard treatment—manual chest compressions—hasn't meaningfully changed in 60 years and achieves less than 10% survival in most communities.In this episode, CPR Therapeutics founder and CEO Norman Paradis joins Dan Mazzucco to talk about developing the first multimodal automated CPR system. They discuss why emergency medicine gets "hand-me-downs" from cardiology, how circumferential compression delivers five times more force without breaking ribs, navigating exception from informed consent trials, building strategic relationships with major device companies, and why EFIC trial requirements create both the highest barrier and the strongest competitive moat.This conversation is for medtech innovators who recognize that sometimes the biggest unmet needs hide in plain sight because no one wants to fund the early-stage R&D, and who understand that regulatory barriers can become competitive advantages if you're willing to climb them first.Norman Paradis, MD, is the Founder and CEO of CPR Therapeutics, an NIH and NSF-funded medical device startup developing the first effective integrated system for cardiopulmonary resuscitation. He is Emeritus Professor of Emergency Medicine at Dartmouth and former Chief of Emergency Medicine at Dartmouth-Hitchcock Medical Center. Dr. Paradis received his medical degree from Northwestern University Feinberg School of Medicine in 1984 and completed his residency in emergency medicine at USC/LA General Medical Center. He has over 40 years of experience and has been active in biomedical innovation throughout his career, previously holding positions at University of Colorado, Columbia University, NYU, and Medical College of Virginia. Dr. Paradis served on the American Heart Association's Advanced Cardiac Life Support (ACLS) Subcommittee for over 10 years, is a founding member of SAEM's Reperfusion Working Group, and serves on editorial boards of The American Journal of Emergency Medicine, Resuscitation, and JAMA's Critical Illness section. He has published more than 50 papers in cardiology, critical care, and emergency medicine, and is senior editor of Cardiac Arrest: The Science and Practice of Resuscitation Medicine. Prior to CPR Therapeutics, he contributed to the development of NT-ProBNP (a widely used heart failure biomarker) and worked with multiple resuscitation technology startups.

Note: Dan's opening statement that this was the "last" episode in the season was just wrong. This interview was so good that it had to jump the queue.A physician treating patients all day sees exactly what devices and treatments are needed. An AI engineer two floors up could solve that problem in an afternoon. The question is: how do you get them in the same building?In this episode, Dr. Afshin Safavi, founder of Colorado Health and Tech Centers, joins Dan Mazzucco to discuss building innovation ecosystems through strategic real estate development. Their wide-ranging discussion explores a three-tier support model (space, funding, and mentorship) for early-stage companies; why mixing biotech, quantum, AI, cybersecurity, and space companies under one roof creates unexpected collaborations; Dr. Safavi's venture studio model; and the value of lunch-and-learns, among other things.This conversation is for medtech founders skeptical about "value-adds" in innovation hubs.Dr. Afshin Safavi is a founder, councilman, consultant, board member, entrepreneur, and investor in biotechnology, pharmaceutical, animal health, technology, and real-estate sectors with multi-billion-dollar turnovers in biological products and is responsible for multiple drug products in the market today. He is the founder of Colorado Health and Tech Centers (CHTC). Prior to that, he founded BioAgilytix Labs, one of the most successful multi-billion-dollar Contract Research Organizations known internationally. He has extensive experience establishing and leading teams in start-ups, as well as Fortune 500 biotech and pharmaceutical companies. He has worked with clients and companies in more than 30 countries.

A family tragedy exposes the massive gap between how well we fund cardiovascular disease versus conditions that affect one in three women; an entrepreneur decides to build the missing solution.In this episode, Avana Health CEO and Co-Founder Peter Pacult joins Dan Mazzucco to talk about transforming personal loss into clinical innovation — navigating the underfunding crisis in women's health, strategic pivoting from postpartum hemorrhage to acute heavy menstrual bleeding, creatively designing a Phase 1 trial to serve a dual purpose as a pathology study, and building partnerships by understanding what truly matters to each stakeholder in healthcare.This conversation is for medtech entrepreneurs who recognize that the biggest opportunities often hide in the areas that have been most neglected and who are ready to build solutions with both humility and strategic precision.Peter Pacult, MBA, is the CEO and Co-Founder of Avana Health, a clinical-stage women's health company focused on treating critical unmet needs in uterine health. With over 20 years of experience in finance and life sciences, he has led multi-million dollar drug development programs and built high-performance teams from the ground up. Peter serves on the steering committee for the Gates Foundation and NIH Innovation Equity Forum for women's health, and holds advisory roles with the Women's Health Catalyst and the Turing Institute's AI for Women's Health Working Group. He holds an MBA from the University of Michigan Ross School of Business with a focus on leadership and strategy, and a BA in History from Northwestern University. At Avana Health, Peter is developing a novel drug-device platform to treat abnormal uterine bleeding (affecting at least one in three women) and postpartum hemorrhage (the leading cause of maternal death globally), with the goal of making treatment accessible in low-resource settings and maternal care deserts.

What happens when a marine biologist-turned recruiter teaches herself to code and ends up building FDA-regulated medical devices — all through the power of being "really nosy" about how teams work?In this episode, TechSlice CEO Juliana Buonanno joins Dan Mazzucco to talk about navigating the intersection of software development and medical device regulation — from her unconventional path into medtech, to cash-plus-equity partnership models that align founder and vendor incentives, to the critical pitfalls that sink medical software startups (over-engineering early prototypes, skipping regulatory pathways, hiring generic dev shops).This conversation is for medtech founders who know that building regulated products requires more than just great code — it requires partners who understand clinical workflows, FDA expectations, and when to say no to shiny features.Juliana Buonanno is the CEO (Emeritus) of TechSlice, a Maryland-based software development agency helping physician-entrepreneurs and MedTech innovators bring new medical and security technologies to life. Over the past eight years, She has led and advised startups and technical teams through the challenges of building FDA-regulated products—from early concept to market-ready solutions.Before founding TechSlice, Juliana helped lead an organizational transformation that turned a mid-sized software firm from a $1M annual loss into profitability within a year. At TechSlice, she has overseen the creation of medical monitoring devices, AI-driven diagnostic tools, and other products that sit at the intersection of healthcare and technology. Her work centers on improving how complex, regulated technologies are built—making the process faster, more transparent, and more effective.

Ann's passion lies in forging genuine connections to cultivate collaboration and unlock collective potential, driven by a desire to make a positive impact.

What happens when a deeply personal experience exposes a blind spot in women’s health and a team of entrepreneurs decides to build the device that should have existed all along?In this episode, CleoCare co-founder Frederico Stock joins Dan Mazzucco to talk about turning real-world unmet need into a clinically meaningful product — navigating validation, usability, population risk, and med-device development trade-offs along the way.This conversation is for entrepreneurs who build because problems in medicine won’t leave them alone.

Dan Mazzucco summarizes Season 1 of Life Science Insights and provides some teasers for Season 2.

Is your science truly investable, or just interesting?Learn how early development decisions determine whether academic science can realistically become a drug, and how industry evaluates translatability long before the clinic.This episode helps you understand what it really takes to turn promising academic science into a viable drug program. Dr. Vijayakumar explains how early development decisions, often made long before investors or regulators are involved, can determine whether a program succeeds or quietly fails. You’ll learn how industry evaluates “translatability,” how formulation and development strategy shape everything downstream, and why great science alone is not enough. If you want to know whether your research can realistically become a drug, and what thinking must change when moving from lab to clinic, this conversation provides a clear, grounded roadmap.

Know when to spin out your technology.This conversation helps academic innovators decide whether (and when) spinning out a company is the right move. Dr. Riley shares a practical framework for assessing commercialization readiness, beyond publications and grant success. You’ll learn how timing, team composition, and institutional context affect outcomes, and why spinning out too early can be as risky as waiting too long. If you’re wrestling with whether to license, form a startup, or keep developing your technology in the lab, this episode offers clarity, perspective, and decision-making confidence grounded in real translational experience.

Entrepreneurship without the mythology.An honest look at what it takes to build a medtech company, from customer discovery to leadership realities beyond the technology.This episode gives an honest look at what it actually means to build and lead a medtech company. Eric Sugalski draws on experience as a repeat founder to explain the realities behind product development, customer discovery, and operational execution. You’ll gain insight into how founders spend their time, how service and product business models differ, and why leadership discipline matters as much as innovation. If you’re considering entrepreneurship or are already in it, this conversation helps align expectations with reality and prepares you for the non-technical challenges that define early company success.

Design discipline is your competitive advantage.Discover how voice-of-customer insights and design controls enable strong science to become products that regulators clear and clinicians adopt.This episode explains why many medical products fail despite strong science, and how structured design thinking can dramatically improve outcomes. John Crombie shows how voice-of-customer insights and design controls translate clinical needs into fundable, buildable, and approvable products. You’ll learn why these processes matter to regulators and investors, and how they protect innovation rather than slow it down. For academic and early-stage founders who see design controls as bureaucracy, this conversation reframes them as powerful tools for reducing risk and increasing the chance your product actually reaches patients.

Investors fund programs with a clear path to launch.Understand why manufacturing and safety strategy matter early—and how CMC and tox shape investor confidence and program value.This episode demystifies CMC and toxicology—and explains why they matter far earlier than most founders expect. Dr. Silvon shows how manufacturing and safety planning shape investor confidence, regulatory credibility, and program value. You’ll learn what questions investors are asking even when they don’t say so, and how early technical rigor can de-risk your program. If you’ve ever felt unprepared discussing development strategy, scalability, or safety planning, this conversation gives you the understanding and language needed to engage confidently and position your company for funding and long-term success.

Regulation doesn’t have to be a black box.Learn how and when to engage FDA, what regulators expect early, and how smart interaction reduces risk and wasted effort.This episode helps founders understand how to engage FDA early and productively. Dr. Glass explains when to initiate regulatory conversations, what agencies are really looking for, and how early feedback can shape smarter development strategies. You’ll learn how to avoid common regulatory missteps and how to view FDA as a partner in risk reduction rather than an obstacle. For academic and first-time founders who find regulation intimidating or opaque, this conversation brings clarity, structure, and confidence to one of the most critical (and misunderstood) parts of building a life-science company.